
    
      Inclusion criteria:

        -  Male or female >= 18

        -  No previous CHT or targeted therapies. Previous adjuvant or neo-adjuvant treatment is
           permitted if completed â‰¥ 6 months before study inclusion.

        -  ECOG performance status 0-1

        -  Adequate organ functions defined as follows:

        -  Neutrophils >= 1.5 x 109/L, platelets >= 100 x 109/L, and hemoglobin >= 9 g/dL

        -  Bilirubin level either normal or < 1.5 x ULN

        -  ASAT and ALAT <= 2.5 x ULN (<= 5 x ULN if liver metastasis are present)

        -  Serum creatinine <1.5 x ULN

        -  Written informed consent given before the randomization, according to International
           Conference on Harmonization/Good Clinical Practice (ICH/GCP)

      Exclusion criteria:

        -  Symptomatic brain metastases

        -  Any investigational agent(s) within 4 weeks prior to study entry

        -  Clinically relevant coronary artery disease or a history of a myocardial infarction
           within the last 12 months

        -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

        -  Patients with known allergy to any other components of the study drugs

        -  History or presence of other disease, metabolic dysfunction, physical examination
           finding, or clinical laboratory finding giving reasonable suspicion of a disease or
           condition that contraindicates use of an investigational drug or patient at high risk
           from treatment complication

        -  Known drug abuse/ alcohol abuse

        -  Legal incapacity or limited legal capacity

        -  Medical or psychological condition which in the opinion of the investigator would not
           permit the patient to complete the study or sign meaningful informed consent

        -  Clinically relevant peripheral neuropathy

        -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
           the cervix (Patients with a previous malignancy but without evidence of disease for 5
           years will be allowed to enter the trial)

        -  Pregnancy or breast feeding. Women of childbearing potential and their parents must be
           willing to practice acceptable methods of birth control to prevent pregnancy

        -  Presence of any psychological, familial, sociological or geographical condition
           potentially hampering compliance with the study protocol and follow-up schedule
    
  